ERBB2 and breast cancer: Additionally, in the setting of anti-HER2 mAbs therapy in BC patients, although pilot clinical trials assessing the delivery of neoadjuvant anti-HER2 mAbs therapy up to 7 days before surgery found it to be safe nearly 20 years ago [100], not many clinical trials employing such immunotherapy during the IPP have been conducted.